NR3C2 and heart failure: In addition to the foundation quadruple heart failure therapy (beta blockers, mineralocorticoid receptor antagonists, angiotensin receptor/neprilysin inhibitor, SGLT2i), recent advances in heart failure therapy have shown to improve patient outcomes.